Kyoung-Min Park

Prof. Dr. Kyoung-Min Park

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2012 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
KPKyoung-Min Park
Kyoung-Min Park
YKYou‐Ho Kim
You‐Ho Kim
FMFrancis E. Marchlinski
Francis E. Marchlinski

5 March 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
SLSung Ho Lee
Sung Ho Lee
MLMi Yeon Lee
Mi Yeon Lee
JKJeonggyu Kang
Jeonggyu Kang
HCHyo‐In Choi
Hyo‐In Choi
SLSeung-Jae Lee
Seung-Jae Lee
KPKyoung-Min Park
Kyoung-Min Park
Background: The ECG is a simple, noninvasive screening method for cardiovascular disease and arrhythmia. The impact of ECG abnormality on mortality is not certain in low‐risk populations. To address this, we evaluated the association between ECG abnormality and mortality. Methods and Results: We retrospectively assessed baseline ECG and all‐cause mortality and cardiovascular mortality in 660 383 patients presenting for medical check‐ups. Baseline ECG abnormalities were classified according to the Minnesota Code. Among the total 660 383 participants, 23 609 (3.6%) had major and 110 038 (16.7%) had minor ECG abnormalities. All‐cause mortality occurred in 7751 patients (1.1%) and cardiovascular mortality in 1180 (0.18%) over a median follow‐up period of 8.8 years. Major ECG abnormalities were associated with all‐cause mortality (hazard ratio [HR], 1.11 [95%, 1.03–1.2]) and cardiovascular mortality (HR, 1.92 [95% CI, 1.63–2.27]) compared with no ECG abnormalities. All‐cause mortality was associated with right atrial enlargement (HR, 2.11 [95% CI, 1.1–4.07]), left atrial enlargement (HR, 1.76 [95% CI, 1.1–2.84]), sinus tachycardia (HR, 1.52 [95% CI, 1.15–2.01]), complete atrioventricular block (HR, 2.1 [95% CI, 1.05–4.2]), atrial fibrillation (HR, 1.52 [95% CI, 1.26–1.84]), and left ventricular hypertrophy (HR, 1.15 [95% CI, 1.02–1.3]). Cardiovascular mortality was associated with left atrial enlargement (HR, 4.52 [95% CI, 2.15–9.5]), atrial fibrillation (HR, 3.22 [95% CI, 2.33–4.46]), left ventricular hypertrophy (HR, 1.72 [95% CI, 1.35–2.19]), major Q‐wave abnormality (HR, 1.6 [95% CI, 1.08–2.39]), and major ST‐T abnormality (HR, 1.76 [95% CI, 1.01–3.04]). Conclusions: ECG abnormalities, including left atrial enlargement, left ventricular hypertrophy, atrial fibrillation, and major Q‐wave and ST‐T abnormalities, were associated with cardiovascular mortality in a low‐risk population.

1 April 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
KPKyoung-Min Park
Kyoung-Min Park
SISung Il Im
Sung Il Im
SPSeung-Jung Park
Seung-Jung Park
JKJune Soo Kim
June Soo Kim
YOYoung Keun On
Young Keun On

13 June 2015 in The Journal of Clinical Hypertension
Verified
Journal Article
Closed access
PDF file
YKYoung‐Joo Kim
Young‐Joo Kim
JAJae Ki Ahn
Jae Ki Ahn
KSKyung‐A Shin
Kyung‐A Shin
CKChul‐Hyun Kim
Chul‐Hyun Kim
YLYoon‐Hee Lee
Yoon‐Hee Lee
KPKyoung-Min Park
Kyoung-Min Park

17 July 2025 in European Heart Journal - Digital Health
Verified
Journal Article
Open access
DHDavid Hong
David Hong
SSSung-Hee Song
Sung-Hee Song
HSHeayoung Shin
Heayoung Shin
MBMinjung Bak
Minjung Bak
JKJuwon Kim
Juwon Kim
KPKyoung-Min Park
Kyoung-Min Park
Aims: Heart failure with preserved ejection fraction (HFpEF) is difficult to diagnose due to the lack of a definitive diagnostic marker; multiple tests are required, including advanced evaluations. This study aimed to develop an artificial intelligence (AI)-enabled electrocardiogram (ECG) model for predicting HFpEF. Methods and results: This retrospective cohort study included patients from a single tertiary centre who underwent echocardiography, N-terminal prohormone of B-type natriuretic peptide measurement, and ECG within a defined timeframe. Patients were classified as HFpEF (HFA-PEFF score ≥5) or control (HFA-PEFF score <5). Patients were divided into training, validation, and test subsets at a 7:1:2 ratio for model development and validation. Using the collected ECGs, a convolutional neural network was trained to predict HFpEF; its performance was assessed using the area under the receiver operating characteristic curve (AUROC). Among the 13 081 patients included, 5795 (44.3%) were classified as HFpEF and 7286 (55.7%) were classified as control. The AI-enabled ECG model demonstrated good discriminative performance [AUROC 0.81; 95% confidence interval (CI) 0.79–0.82]. Subgroup analyses stratified by HFpEF risk factors confirmed consistent model performance. Prognostic evaluation revealed that patients with a positive AI-ECG classification experienced significantly worse outcomes relative to those with a negative classification, including higher risks of cardiac death (1.1% vs. 0.1%; hazard ratio 9.56; 95% CI 1.24–73.53; P = 0.030) and heart failure hospitalization (2.8% vs. 0.6%; hazard ratio 5.91; 95% CI 2.08–16.81; P = 0.001) at 5 year. Conclusion: The AI-ECG model is a reliable tool for predicting HFpEF, as defined by the HFA-PEFF score, and effectively stratifies patients according to prognosis. Integration of this model into clinical practice may simplify and enhance the diagnostic process for HFpEF.

8 September 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JKJu Youn Kim
Ju Youn Kim
HPHyoung‐Seob Park
Hyoung‐Seob Park
HPHyung Wook Park
Hyung Wook Park
ECEue-Keun Choi
Eue-Keun Choi
JPJin‐Kyu Park
Jin‐Kyu Park
KPKyoung-Min Park
Kyoung-Min Park
Background: Atrial fibrillation (AF) is associated with an increased risk of poor cardiovascular outcomes; appropriate rhythm control can reduce the incidence of these adverse events. Therefore, catheter ablation is recommended in symptomatic patients with AF. The aims of this study were to compare AF‐related outcomes according to a baseline symptom scale score and to determine the best treatment strategy for asymptomatic patients with AF. Methods and Results: This study enrolled all patients who completed a baseline Atrial Fibrillation Effect on Quality‐of‐Life (AFEQT) survey in a prospective observational registry. The patients were divided into 2 groups according to AFEQT score at baseline; scores ≤80 were defined as symptomatic, whereas scores >80 represented asymptomatic patients. The primary outcome was defined as a composite of hospitalization for heart failure, ischemic stroke, or cardiac death. This study included 1515 patients (mean age: 65.7±10.5 years; 998 [65.9%] men). The survival curve showed a poorer outcome in the symptomatic group compared with the asymptomatic group (log‐rank P =0.04). Rhythm control led to a significantly lower risk of a composite outcome in asymptomatic patients (hazard ratio [HR], 0.47 [95% CI, 0.27–0.84], P =0.01). Rhythm control was associated with more favorable composite outcomes in the asymptomatic group with paroxysmal AF, left atrium diameter ≤50 mm, and CHA 2 DS 2 ‐VASc score ≥3. Conclusions: Symptomatic patients with AF experienced more adverse outcomes compared with asymptomatic patients. In asymptomatic patients with AF, a strategy of rhythm control improved the outcomes, especially with paroxysmal AF, smaller left atrium size, or higher stroke risk. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02786095.